Utilising novel antimicrobial peptides identified from the rumen microbiome as a potential treatment for multiple A. baumannii strains
Utilising novel antimicrobial peptides identified from the rumen microbiome as a potential treatment for multiple A. baumannii strains
复制标题
利用从瘤胃微生物组中鉴定出的新型抗菌肽作为多种鲍曼不动杆菌菌株的潜在治疗方法
DOI：
10.1099/acmi.ac2019.po0043
复制
发表时间：
2019
影响因子：
--
通讯作者：
Alexander P
中科院分区：
文献类型：
--
作者：
Alexander P
抗生素和抗菌素耐药性是一个全球性问题，不仅关系到医疗和兽医治疗，也关系到经济发展。已知对抗微生物药物产生耐药性的关键细菌病原体之一是鲍曼不动杆菌，它是ESKAPE病原体之一。鲍曼不动杆菌是一种需氧革兰氏阴性球芽杆菌，与菌血症、尿路感染和呼吸机相关性肺炎有关，通常被视为机会致病菌。先前的研究表明，鲍曼不动杆菌临床菌株对新型抗菌肽敏感，特别是那些从瘤胃宏基因组数据集中鉴定出来的抗菌肽。使用标准化的96孔MIC测试，将3种抗菌肽（Lynronne-1, Lynronne-2, Lynronne-3，确定为Huws实验室先前研究项目的一部分）与多种鲍曼不动杆菌菌株进行比较，以显示对更多种菌株的治疗效果。在检测的菌株中，许多临床分离株显示出耐药性（亚胺培南耐药，OXO-23/OXO-50）。结果表明，抗菌肽对细菌生长有明显的抑制作用。所使用的3种多肽之间也存在差异，Lynronne-1似乎在大多数测试菌株中具有最低的MIC。作为该项目的一部分，进一步的研究将利用其他已识别的抗菌肽，包括合理设计的肽，以及潜在地使用另一个胃肠道微生物组宏基因组数据集来识别更多的新型抗菌肽。
Antibiotic and antimicrobial resistance is a global issue, not only for medical and veterinary treatment, but also for economic development. One of the critical bacterial pathogens known to develop resistance to antimicrobial agents is Acinetobacter baumannii, one of the ESKAPE pathogens. A. baumannii is an aerobic Gram-negative coccobacillus bacterium associated with bacteraemia, urinary tract infections and ventilator-associated pneumonia, and is typically viewed as an opportunistic pathogen. Previous research has shown that clinical strains of A. baumannii have susceptibility to novel antimicrobial peptides, specifically those identified from a rumen metagenomic dataset. Using standardised 96 well MIC testing, 3 antimicrobial peptides (Lynronne-1, Lynronne-2, Lynronne-3, identified as part of a previous research project by the Huws Lab) were compared against multiple strains of A. baumannii, in order to show efficacy of treatment against a wider variety of strains. Of the strains tested, a number were clinical isolates with demonstrated resistance (imipenem resistant, OXO-23/OXO-50). The results show that the antimicrobial peptides had noticeable inhibitory effects on the bacterial growth. There was also variation between the 3 peptides utilised, with Lynronne-1 appearing to have the lowest MIC over the majority of the strains tested. Further research as part of this project will utilise other identified antimicrobial peptides, including rationally designed peptides, as well as potentially using another gastrointestinal microbiome metagenomic dataset to identify a greater number of novel antimicrobial peptides.
瘤胃微生物组：新型抗菌药物发现的尚未开发的资源
DOI：
10.1101/148221
发表时间：
2017
期刊：
--
影响因子：
--
作者：
Oyama L
通讯作者：
Oyama L